All In Biotech

Drug Trial Radar · NCT06941415

Bumetanide vs. Furosemide in Cirrhosis

Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial

Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jun 3, 2026

Primary completion

Mar 1, 2029

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Stacy JohnsonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.

Conditions

  • Cirrhosis

Interventions

  • BumetanideDrug

    Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders

  • FurosemideDrug

    Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in weightTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Utah Hospital

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.